Perimenopause and migraine

Migraine is three times more common in women than men, and estrogen is the main reason. For many women it gets worse in perimenopause, when estrogen stops following a predictable monthly curve and starts swinging. The good news is that migraine without aura often eases after menopause. The complication is that the treatments for perimenopause and the treatments for migraine interact, and the presence or absence of aura changes what is safe. This guide explains the pattern and how to manage both conditions at once.

Why perimenopause makes migraine worse

In a regular cycle, the drop in estrogen just before a period is a well-established trigger for migraine without aura. Perimenopause multiplies those drops. Cycles shorten, lengthen and skip; estrogen can spike higher than usual and then fall further. As the 2026 review in Headache, the journal of the American Headache Society, puts it, unstable estradiol and progesterone during perimenopause worsen both the frequency and the predictability of attacks. Sleep disruption from night sweats, mood changes and weight gain add their own triggers; see why perimenopause wakes you at 3 a.m..

The size of the effect was measured in the American Migraine Prevalence and Prevention Study. Among 3,664 women with migraine aged 35 to 65, 8.0 percent of premenopausal women had high-frequency headache (10 or more headache days a month), compared with 12.2 percent of perimenopausal and 12.0 percent of postmenopausal women. After adjusting for age, income, depression, body mass index, preventive medication and medication overuse, perimenopausal women still had 1.42 times the odds of high-frequency headache. For postmenopausal women the increase was no longer significant once medication overuse was accounted for, suggesting that overuse of acute medication, rather than hormones, may drive much of the postmenopausal excess.

Two practical lessons follow. Perimenopause is a period when migraine prevention deserves to be optimized rather than waited out. And counting your acute medication days matters, because medication overuse headache is a real and treatable cause of frequent headache at this age.

Aura changes the picture

	Migraine without aura	Migraine with aura
Typical hormonal trigger	Estrogen withdrawal (the premenstrual drop)	High estrogen levels
Course after menopause	Often improves as estrogen stabilizes at a low level	Tends to persist
Stroke risk	Not meaningfully raised	Independently raised; combined with smoking or estrogen-containing contraception, higher still
Combined hormonal contraception (ethinylestradiol)	Usually acceptable if no other vascular risk factors	Avoided; headache and contraception societies advise against it
Menopausal hormone therapy	Low-dose transdermal estradiol, continuous, generally acceptable	Low-dose transdermal estradiol, continuous, generally acceptable; avoid high-dose oral estrogen

The European Headache Federation consensus found that the quality of evidence on stroke risk with hormonal contraceptives in migraine is low, but that available data suggest combined hormonal contraceptives further raise ischemic stroke risk in women with migraine with aura, so its statements favor safety and recommend avoiding them in that group. This matters in perimenopause because combined pills are sometimes used to control erratic cycles and symptoms; women with aura need a different approach, usually a progestogen-only method, with transdermal estradiol added if needed for hot flashes.

Menopausal hormone therapy is a different matter. As MacGregor’s review states, in contrast to contraceptive doses of ethinylestradiol, migraine aura does not contraindicate physiological doses of natural estrogen. The Menopause Society’s position statement emphasizes individualizing type, dose and route; for women with migraine, the 2026 Headache review notes that low-dose transdermal estrogen appears safer and better tolerated than oral estrogen, which, particularly at higher doses, may worsen migraine and raise vascular risk, especially with aura.

Hormone therapy in perimenopause: how to do it without making migraine worse

If hot flashes, night sweats or sleep are bad enough to treat, hormone therapy can help the migraine as well as the perimenopause, because it smooths out the estrogen swings that trigger attacks. The headache literature agrees on a few principles:

• Steady, not cyclical. Continuous estrogen rather than regimens with hormone-free intervals, so there is no built-in estrogen drop. If a progestogen is needed to protect the uterus, continuous progestogen (daily, or via a levonorgestrel IUD) is preferred to cyclical courses, which can provoke attacks.
• Transdermal, low dose. Patches or gel give more stable blood levels than pills and avoid first-pass liver effects. Use the lowest dose that controls hot flashes.
• Timing. Starting hormone therapy early in perimenopause, while your own estrogen is still surging, can sometimes worsen migraine because levels are then high and unstable. Headache specialists often favor cycle control first (for example, a progestogen-only method) and introduce estradiol as natural production declines.
• Reassess. Some women improve, some worsen, and some see no change. If attacks increase after starting, the dose or route can be adjusted rather than abandoning treatment.

If you cannot or prefer not to use estrogen, The Menopause Society’s non-hormonal options for hot flashes include SNRIs such as venlafaxine, which also have evidence as migraine preventives, giving one drug for two problems. Fezolinetant treats hot flashes but has no effect on migraine.

Migraine treatment at midlife

Standard migraine care continues, with adjustments for age and vascular risk:

• Prevention. Beta-blockers, topiramate, certain antidepressants and candesartan remain first-line; CGRP monoclonal antibodies and gepants are newer preventive options with good tolerability. Topiramate can affect bone and cognition, both of which deserve attention in midlife.
• Acute treatment. Triptans and NSAIDs remain central, but triptans constrict blood vessels and are avoided with uncontrolled hypertension, heart disease or prior stroke. Gepants and the ditan lasmiditan do not constrict vessels and are options when vascular risk is a concern. Limit acute medication to fewer than 10 days a month (triptans, combination analgesics) or 15 days (simple analgesics) to avoid medication overuse headache.
• Blood pressure, cholesterol and smoking. Midlife is when these rise, and in migraine with aura they compound stroke risk. Treating them is part of migraine care.

When to seek care urgently

Call 911 or go to an emergency department for:

• A sudden, severe “worst ever” headache reaching peak intensity within a minute.
• A new aura lasting more than an hour, or weakness, numbness, trouble speaking or vision loss that does not resolve as your usual aura does.
• Headache with fever and stiff neck, after a head injury, or with confusion or seizure.
• A first aura ever, or a clear change in your aura pattern, at this age. New aura after 40 needs evaluation to exclude a stroke or transient ischemic attack before it is attributed to migraine.

Putting the two plans together

Make sure your headache clinician knows every hormone you use, including contraceptives and vaginal estrogen, and that your menopause clinician knows whether you have aura and what preventives you take. Keep a headache diary that also logs periods, hot flashes and sleep; patterns often emerge within two to three months. A menopause specialist comfortable with transdermal regimens, or an MSCP-certified clinician, is a good match for this situation, and our directory can help you find one.